Amboy Street Ventures Joins HerMD’s $18M Round

Amboy Street invests in HerMD which offers menopause and sexual health care through a hybrid delivery model with in-person and virtual services.

Amboy Street Ventures is excited to announce its latest investment in HerMD, a blossoming player in the menopause and sexual health space. HerMD offers novel, research-backed procedures to treat menopause and sexual health related issues while leveraging a hybrid delivery model to provide both in-person and virtual care.

In the US, more than 1M women experience menopause each year, but it is under-researched and often ignored in healthcare. Only 20% of OBGYNs are trained on menopause, leaving most women to suffer, silently, with very few options for treatment.

HerMD is closing the gender health gap by utilizing groundbreaking technology to treat menopause and sexual health related issues. Dr. Somi Javaid, founder of HerMD and certified menopause and sexual health expert, is committed to providing novel medical services that are proven to be effective but are unavailable at most OBGYN offices.

From standard hormone therapy to novel procedures like Sonata, a treatment for uterine fibroids, and Votiva, a treatment for pelvic floor issues, HerMD provides a whole suite of offerings focused on menopause, reproductive and sexual health care.

Amboy Street is excited to support HerMD in this $18M round alongside notable co-investors Jazz Venture Partners and B-Flexion. With the funding, the company will expand beyond its 5 brick-and-mortar locations, opening a first clinic in the New York City area and a second Nashville-area clinic.

“We will also be introducing e-commerce and physician-curated products,” Javaid said. “Hospital-based systems, and relationships like that, is another thing that we would love to do. We rely on hospitals for imaging, primary care and obstetric and oncology care, but a lot of hospital systems say they struggle because their providers aren’t trained in menopause and sexual health. They need a partner like us, and I see HerMD having over 200 clinics in the future.”

Carli Sapir of Amboy Street Ventures is excited for what the future holds for HerMD.

“HerMD’s incredible traction is no surprise. They’re delivering an outstanding standard of menopause and sexual healthcare – two spaces that are drastically underserved. As Amboy Street Ventures is focused on backing startups that progress the women’s health and sexual wellness space, we are proud to support HerMD. And personally as a HerMD patient, I am eternally grateful for their expertise, which I could not find elsewhere.”

HerMD is the latest to join ASV’s growing portfolio of brands pioneering women’s health and sexual health solutions alongside Hey Jane, leading tele-health abortion provider, Contraline, the maker of male birth control and Dame Products, a leading female-focused sexual wellness brand. See the full portfolio here.

Continue Reading

Amboy Street Invests in Alloy’s $16M Series A

Amboy Street Ventures is excited to announce its latest investment in Alloy Women’s Health, a digital health company committed to providing women the care they need through menopause and beyond.

Top 10 Deals of 2024: BillionToOne Becomes a Unicorn

In this blog, we unpack prenatal genetic screening company, BillionToOne's $130 million Series D raise to showcase the increasing number of women’s health companies reaching unicorn status. We are seeing women’s health companies close considerable growth rounds while early-stage funding remains robust.

Top 10 Deals of 2024: Urinary Incontinence MedTech $3.7B Acquisition

This week we explore a major acquisition in a segment of women’s health that is often stigmatized yet universally experienced by women at some point in their lifetime: urinary incontinence.

Amboy Street Invests in Alloy’s $16M Series A

Amboy Street Ventures is excited to announce its latest investment in Alloy Women’s Health, a digital health company committed to providing women the care they need through menopause and beyond.

Top 10 Deals of 2024: BillionToOne Becomes a Unicorn

In this blog, we unpack prenatal genetic screening company, BillionToOne's $130 million Series D raise to showcase the increasing number of women’s health companies reaching unicorn status. We are seeing women’s health companies close considerable growth rounds while early-stage funding remains robust.

Fast track our industry.
Get in touch today.